Please assess the completion status of the following clinical trial:

Trial Title: Combination of Remifentanil and Flurbiprofen in Sedation and Analgesia for ESWL of Pancreatic Stone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged 18-65 years~* ASA I-II~* ESWL indication was met~Exclusion Criteria:~* patients with hypertension~* patients compromised in cardiopulmonary function~* patients undergoing ESWL for the second or more times

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Rem group (Type: ACTIVE_COMPARATOR): Patients in this group receive single infusion of remifentanil with target concentration infusion.
- Flur group (Type: EXPERIMENTAL): Patients in this group receive both infusion of flurbiprofen and remifentanil

Based on this trial design, predict the completion outcome and termination type (if applicable).